CDK13
MOLECULAR TARGETcyclin dependent kinase 13
CDK13 (cyclin dependent kinase 13) is targeted by 19 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CDK13
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | alvocidib | 4.52 | 91 |
| 2 | foretinib | 4.34 | 76 |
| 3 | doramapimod | 4.06 | 57 |
| 4 | dinaciclib | 3.87 | 47 |
| 5 | fasudil | 3.66 | 38 |
| 6 | bms 387032 | 3.47 | 31 |
| 7 | linifanib | 3.33 | 27 |
| 8 | at 7519 | 3.33 | 27 |
| 9 | lestaurtinib | 3.04 | 20 |
| 10 | defosbarasertib | 2.89 | 17 |
| 11 | pf 00562271 | 2.77 | 15 |
| 12 | bms 345541 | 2.71 | 14 |
| 13 | ast 487 | 2.56 | 12 |
| 14 | defactinib | 2.48 | 11 |
| 15 | rg 547 | 2.08 | 7 |
| 16 | amg 900 | 2.08 | 7 |
| 17 | ravoxertinib | 2.08 | 7 |
| 18 | istisociclib | 2.08 | 7 |
| 19 | hydroxyfasudil [Supplementary Concept] | 0.69 | 1 |
About CDK13 as a Drug Target
CDK13 (cyclin dependent kinase 13) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 19 compounds with documented CDK13 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CDK13 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.